Business
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
HENDERSON, Nev., March 25, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates.
About this update from Zura Bio Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f4a1813a58b80ab0a2a7a2ee3f0b8ea1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0tFoW.3WTD9QevUqIZj7Hw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f4a1813a58b80ab0a2a7a2ee3f0b8ea1","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/WUGtek.Jg7hdAUTdZFUEUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f4a1813a58b80ab0a2a7a2ee3f0b8ea1","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline","length":140,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc)","length":76,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024","length":165,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS)","length":150,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":531,"olType":false},{"type":"text","content":"HENDERSON, Nev., March 25, 2025--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates.","length":342,"tagName":"p"},{"type":"text","content":""In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a leading presence in immunology," said Robert Lisicki, Chief Executive Officer of Zura Bio. &q...